


# Relapsed and Refractory Multiple Myeloma

Multiple myeloma (MM) is an incurable blood cancer<sup>1</sup> that starts in the bone marrow<sup>2</sup> and is characterised by an excessive proliferation of plasma cells<sup>2</sup>




**38,000** new MM cases in Europe each year<sup>3</sup>

**28%** of MM patients die within one year of diagnosis<sup>4</sup>




Up to **47%**


of people diagnosed with MM die within 5 years<sup>5</sup>



Treatment may result in **remission** but patients will most likely relapse<sup>1</sup>



**Relapsed MM** is when the cancer returns after treatment or a period of remission<sup>1</sup>



**Refractory MM** is when the cancer is not responsive to therapy<sup>6</sup>

## Disease burden

Outlook for relapsed and refractory (RR)MM patients has traditionally been poor

Median overall survival is only **5-9 months** depending on the number of prior lines of therapy<sup>7,8</sup>



RR MM patients have:

**Physical disease-related symptoms<sup>9</sup>, including...**


- Bone pain or fractures
- Fatigue, shortness of breath or weakness
- Unusual bleeding or bruising more easily than normal

**Cumulative treatment-related toxicities<sup>9</sup>, including...**

- Impaired bone marrow reserve

**Emotional symptoms include risk of anxiety and depression due to continual fear of relapse<sup>10</sup>**

## Myeloma follows a pattern of remission and relapse<sup>9,11</sup>



## New targeted treatment options are needed



Currently there is no standard of care to treat RR MM



There is a critical need for new treatment options<sup>7</sup>

Monoclonal antibody (mAb) therapies offer an exciting new treatment option:<sup>12,13</sup>



Harness the patient's own immune system to target the cancer



Only bind to the specific proteins expressed on cancer cells



Multiple modes of action, working by either: triggering the immune system, working to attack cancer cells, blocking signals telling cancer cells to divide or carrying cancer drugs or radiation directly into the cancer cells



Cause fewer side effects than traditional chemotherapy treatments

MAKE BLOOD CANCER VISIBLE People impacted by blood cancer need more than treatment and care. To improve awareness and further support patients and their families, Janssen has launched 'Make Blood Cancer Visible' - a campaign to get people talking about blood cancers and bring forward patient perspectives. #LETSTALKABOUTBLOODCANCER visit [www.facebook.com/letstalkaboutbloodcancer](http://www.facebook.com/letstalkaboutbloodcancer)

**References**

- Multiple Myeloma Research Foundation. Relapsed Myeloma. Available at: <http://www.themmf.org/multiple-myeloma/prognosis/relapsed-multiple-myeloma/> Last accessed February 2016.
- American Society of Clinical Oncology. Multiple myeloma: overview. Available at: <http://www.cancer.net/cancer-types/multiple-myeloma/overview> Last accessed February 2016.
- International Agency for Research on Cancer, GLOBOCAN 2012 database. Available at: <http://globocan.iarc.fr/> Last accessed February 2016.
- Costa LJ, Consalves WI, Kumar SK. Early mortality in multiple myeloma. *Leukemia*. 2015;29:1616-8.
- Cancer Research UK. Myeloma Survival Statistics. Available at: <http://www.cancerresearchuk.org/cancer-info/cancerstats/types/myeloma/survival/multiple-myeloma-survival-statistics> Last accessed February 2016.
- Multiple Myeloma Research Foundation. Refractory Myeloma. Available at: <http://www.themmf.org/multiple-myeloma/prognosis/refractory-multiple-myeloma/> Last accessed February 2016.
- Usmani S, et al. Analysis of overall survival in multiple myeloma patients with ≥3 lines of therapy including a PI and an IMiD, or double refractory to a PI and an IMiD using real-world data. *Haematologica*. 2015;100 (Suppl. 1):S04-5 (abstract E1256).
- Kumar SK, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. *Leukemia*. 2012;26:149-57.
- Dimopoulos MA, et al. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. *Leukemia*. 2014;28:1573-85.
- Myeloma Patients Europe. Report on Myeloma Patient Perspectives. Available at: <http://www.mpeurope.org/publications/reports-and-position-statements/about-mono-clonal-antibodies> Last accessed February 2016.
- Kurtin SE. Relapsed or Relapsed/Refractory Multiple Myeloma. *J Adv Pract Oncol* 2013;4(Suppl 1):5-14.
- Cancer Research UK. About monoclonal antibodies. Available at: <http://www.cancerresearchuk.org/about-cancer/cancers-in-general/treatment/biological/types/about-mono-clonal-antibodies> Last accessed February 2016.
- Mayo Clinic. Monoclonal antibody drugs for cancer: How they work. Available at: <http://www.mayoclinic.org/diseases-conditions/cancer/in-depth/monoclonal-antibody/art-20047808?pg=2>. Last accessed February 2016.